Does the media favor RVMD or CYTK?

In the previous week, Revolution Medicines had 1 more articles in the media than Cytokinetics. MarketBeat recorded 24 mentions for Revolution Medicines and 23 mentions for Cytokinetics. Revolution Medicines' average media sentiment score of 1.39 beat Cytokinetics' score of 0.79 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 20 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 14 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CYTK or TEVA?

In the previous week, Teva Pharmaceutical Industries had 25 more articles in the media than Cytokinetics. MarketBeat recorded 48 mentions for Teva Pharmaceutical Industries and 23 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.79 beat Teva Pharmaceutical Industries' score of 0.77 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 14 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 26 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to CYTK or ONC?

In the previous week, Cytokinetics had 9 more articles in the media than BeOne Medicines. MarketBeat recorded 23 mentions for Cytokinetics and 14 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.90 beat Cytokinetics' score of 0.79 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 14 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CYTK or ROIV?

In the previous week, Cytokinetics had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 23 mentions for Cytokinetics and 18 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.16 beat Cytokinetics' score of 0.79 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 14 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 15 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CYTK or MRNA more profitable?

Moderna has a net margin of -141.43% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Cytokinetics -784.02% N/A -52.86% Moderna -141.43% -28.30% -19.39%

Does the media prefer CYTK or MRNA?

In the previous week, Moderna had 25 more articles in the media than Cytokinetics. MarketBeat recorded 48 mentions for Moderna and 23 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.79 beat Moderna's score of 0.38 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 14 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 17 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 9 Negative mention(s) 1 Very Negative mention(s) Neutral

Cytokinetics (CYTK) Competitors

$77.13 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$77.10 -0.02 (-0.03%)

As of 07/31/2026 07:34 PM Eastern

Compare

CYTK vs. RVMD, TEVA, ONC, ROIV, and MRNA

Should you buy Cytokinetics stock or one of its competitors? MarketBeat compares Cytokinetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytokinetics include Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Roivant Sciences (ROIV), and Moderna (MRNA).

How does Cytokinetics compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Revolution Medicines has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

In the previous week, Revolution Medicines had 1 more articles in the media than Cytokinetics. MarketBeat recorded 24 mentions for Revolution Medicines and 23 mentions for Cytokinetics. Revolution Medicines' average media sentiment score of 1.39 beat Cytokinetics' score of 0.79 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	20 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	14 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.3% of Revolution Medicines shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cytokinetics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A
Cytokinetics	$105.82M	90.70	-$784.96M	-$6.84	N/A

Revolution Medicines has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Cytokinetics	-784.02%	N/A	-52.86%

Revolution Medicines currently has a consensus target price of $144.67, suggesting a potential downside of 22.85%. Cytokinetics has a consensus target price of $99.90, suggesting a potential upside of 29.52%. Given Cytokinetics' higher possible upside, analysts clearly believe Cytokinetics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95

Summary

Revolution Medicines beats Cytokinetics on 8 of the 15 factors compared between the two stocks.

How does Cytokinetics compare to Teva Pharmaceutical Industries?

Cytokinetics (NASDAQ:CYTK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Teva Pharmaceutical Industries had 25 more articles in the media than Cytokinetics. MarketBeat recorded 48 mentions for Teva Pharmaceutical Industries and 23 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.79 beat Teva Pharmaceutical Industries' score of 0.77 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	14 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	26 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Cytokinetics presently has a consensus target price of $99.90, indicating a potential upside of 29.52%. Teva Pharmaceutical Industries has a consensus target price of $42.00, indicating a potential upside of 19.84%. Given Cytokinetics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cytokinetics is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Teva Pharmaceutical Industries has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$105.82M	90.70	-$784.96M	-$6.84	N/A
Teva Pharmaceutical Industries	$17.26B	2.33	$1.41B	$0.60	58.41

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Cytokinetics' net margin of -784.02%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

Cytokinetics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Teva Pharmaceutical Industries beats Cytokinetics on 10 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to BeOne Medicines?

Cytokinetics (NASDAQ:CYTK) and BeOne Medicines (NASDAQ:ONC) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

BeOne Medicines has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$105.82M	90.70	-$784.96M	-$6.84	N/A
BeOne Medicines	$5.34B	6.49	$286.93M	$4.47	70.70

BeOne Medicines has a net margin of 8.94% compared to Cytokinetics' net margin of -784.02%. BeOne Medicines' return on equity of 12.06% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
BeOne Medicines	8.94%	12.06%	6.69%

Cytokinetics presently has a consensus price target of $99.90, indicating a potential upside of 29.52%. BeOne Medicines has a consensus price target of $394.00, indicating a potential upside of 24.68%. Given Cytokinetics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cytokinetics is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88

48.6% of BeOne Medicines shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cytokinetics had 9 more articles in the media than BeOne Medicines. MarketBeat recorded 23 mentions for Cytokinetics and 14 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.90 beat Cytokinetics' score of 0.79 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	14 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Summary

BeOne Medicines beats Cytokinetics on 11 of the 16 factors compared between the two stocks.

How does Cytokinetics compare to Roivant Sciences?

Cytokinetics (NASDAQ:CYTK) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

64.8% of Roivant Sciences shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cytokinetics had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 23 mentions for Cytokinetics and 18 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.16 beat Cytokinetics' score of 0.79 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	14 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	15 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics currently has a consensus target price of $99.90, suggesting a potential upside of 29.52%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential downside of 0.94%. Given Cytokinetics' stronger consensus rating and higher probable upside, equities analysts plainly believe Cytokinetics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Cytokinetics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Roivant Sciences has lower revenue, but higher earnings than Cytokinetics. Roivant Sciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$105.82M	90.70	-$784.96M	-$6.84	N/A
Roivant Sciences	$8.26M	2,952.84	-$299.77M	-$0.60	N/A

Cytokinetics has a net margin of -784.02% compared to Roivant Sciences' net margin of -3,629.19%. Cytokinetics' return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Summary

Cytokinetics beats Roivant Sciences on 9 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Moderna?

Cytokinetics (NASDAQ:CYTK) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, Moderna had 25 more articles in the media than Cytokinetics. MarketBeat recorded 48 mentions for Moderna and 23 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.79 beat Moderna's score of 0.38 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	14 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	17 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cytokinetics has higher earnings, but lower revenue than Moderna. Cytokinetics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$105.82M	90.70	-$784.96M	-$6.84	N/A
Moderna	$2.21B	9.84	-$2.82B	-$7.99	N/A

Moderna has a net margin of -141.43% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Moderna	-141.43%	-28.30%	-19.39%

Cytokinetics presently has a consensus price target of $99.90, indicating a potential upside of 29.52%. Moderna has a consensus price target of $40.00, indicating a potential downside of 27.03%. Given Cytokinetics' stronger consensus rating and higher possible upside, research analysts plainly believe Cytokinetics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82

Cytokinetics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Moderna has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

75.3% of Moderna shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cytokinetics beats Moderna on 9 of the 17 factors compared between the two stocks.

Get Cytokinetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYTK vs. The Competition

Export

Metric	Cytokinetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.60B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-11.28	7.38	282.30	24.66
Price / Sales	90.70	1,182.44	561.34	76.65
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	-14.31	16.96	10.98	6.07
Net Income	-$784.96M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-4.33%	-1.76%	-0.60%	-0.44%
1 Month Performance	-10.82%	-8.38%	-5.20%	-4.81%
1 Year Performance	110.22%	48.40%	62.01%	18.61%

Cytokinetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYTK Cytokinetics	3.4854 of 5 stars	$77.13 flat	$99.90 +29.5%	+110.2%	$9.60B	$105.82M	N/A	250	Trending News Upcoming Earnings Gap Up
RVMD Revolution Medicines	1.9712 of 5 stars	$180.39 -3.1%	$144.06 -20.1%	+412.0%	$39.58B	$11.58M	N/A	250	Positive News Upcoming Earnings Gap Up
TEVA Teva Pharmaceutical Industries	4.0001 of 5 stars	$30.97 -3.3%	$41.78 +34.9%	+127.9%	$36.83B	$17.26B	23.28	33,950	Trending News Earnings Report Analyst Upgrade
ONC BeOne Medicines	4.7057 of 5 stars	$310.58 -0.5%	$390.92 +25.9%	+5.7%	$34.23B	$5.34B	69.48	12,000	Upcoming Earnings
ROIV Roivant Sciences	1.5764 of 5 stars	$34.05 -1.3%	$33.59 -1.3%	+199.8%	$24.82B	$8.26M	N/A	860	Positive News Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYTK) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytokinetics (CYTK) Competitors

CYTK vs. RVMD, TEVA, ONC, ROIV, and MRNA

How does Cytokinetics compare to Revolution Medicines?

Summary

How does Cytokinetics compare to Teva Pharmaceutical Industries?

Summary

How does Cytokinetics compare to BeOne Medicines?

Summary

How does Cytokinetics compare to Roivant Sciences?

Summary

How does Cytokinetics compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytokinetics (CYTK) Competitors

CYTK vs. RVMD, TEVA, ONC, ROIV, and MRNA

How does Cytokinetics compare to Revolution Medicines?

Which has more risk & volatility, RVMD or CYTK?

Does the media favor RVMD or CYTK?

Do institutionals & insiders hold more shares of RVMD or CYTK?

Which has better valuation and earnings, RVMD or CYTK?

Is RVMD or CYTK more profitable?

Do analysts rate RVMD or CYTK?

Summary

How does Cytokinetics compare to Teva Pharmaceutical Industries?

Does the media prefer CYTK or TEVA?

Do analysts prefer CYTK or TEVA?

Which has better valuation & earnings, CYTK or TEVA?

Is CYTK or TEVA more profitable?

Which has more risk and volatility, CYTK or TEVA?

Do institutionals and insiders believe in CYTK or TEVA?

Summary

How does Cytokinetics compare to BeOne Medicines?

Which has better valuation and earnings, CYTK or ONC?

Is CYTK or ONC more profitable?

Do analysts recommend CYTK or ONC?

Do insiders and institutionals believe in CYTK or ONC?

Does the media refer more to CYTK or ONC?

Which has more volatility & risk, CYTK or ONC?

Summary

How does Cytokinetics compare to Roivant Sciences?

Do insiders & institutionals hold more shares of CYTK or ROIV?

Does the media refer more to CYTK or ROIV?

Do analysts rate CYTK or ROIV?

Which has more volatility & risk, CYTK or ROIV?

Which has better earnings and valuation, CYTK or ROIV?

Is CYTK or ROIV more profitable?

Summary

How does Cytokinetics compare to Moderna?

Does the media prefer CYTK or MRNA?

Which has preferable earnings and valuation, CYTK or MRNA?

Is CYTK or MRNA more profitable?

Do analysts prefer CYTK or MRNA?

Which has more risk & volatility, CYTK or MRNA?

Do institutionals and insiders believe in CYTK or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools